The Global Pediatric Interventional Cardiology Market is valued at approximately USD 2.6 billion in 2023 and is projected to grow at a healthy growth rate of more than 5.7% over the forecast period 2024-2032. Pediatric interventional cardiology, a specialized subset of cardiology, employs catheter-based techniques to treat heart disorders in infants, children, and adolescents up to 18 years of age. These techniques, such as balloon angioplasty, coil occlusion, stent implantation, and aortic valve stenosis, offer minimally invasive alternatives to conventional cardiological treatments, thereby reducing post-surgery complications. Consequently, they are extensively utilized in angioplasty, valvuloplasty, coronary thrombectomy, and congenital heart defect correction procedures across clinical testing laboratories, hospitals, cardiac centers, and research institutes.

The market is experiencing robust growth due to the increasing prevalence of congenital cardiac diseases in children, such as atrial septal defect (ASD), atrioventricular canal defect, patent ductus arteriosus (PDA), and ventricular septal defect (VSD). The introduction of novel pediatric interventional cardiology devices, including catheters, bio-absorbable stents, guidewires, balloons, stents, and vascular closure devices, is a significant growth driver. Additionally, the growing inclination toward non-invasive medical treatments, driven by benefits such as lower infection risk, shorter postoperative recovery times, and avoidance of large scars, is bolstering the market growth. Further, rising healthcare expenditure, government initiatives to expedite regulatory procedures, extensive research and development activities, and significant technological advancements in cardiology are creating a positive market outlook.

The key regions considered in the study include Asia Pacific, North America, Europe, Latin America, and the Middle East and Africa. North America dominated the market in 2023, owing to advanced healthcare infrastructure, high healthcare expenditure, and the presence of key market players. The Asia-Pacific region is expected to witness the fastest growth during the forecast period, driven by improving healthcare infrastructure, increasing healthcare spending, and rising awareness regarding pediatric interventional cardiology.

Major market players included in this report are:
Biotronik SE & Co. KG
Boston Scientific Corporation
Cardinal Health Inc.
Edwards Lifesciences Corporation
General Electric Company
Koninklijke Philips N.V.
Lepu Medical Technology (Beijing) Co. Ltd.
Medtronic plc
NuMED Inc.
Siemens Healthineers AG
Terumo CorporationW. L. Gore & Associates Inc.
B. Braun Melsungen AG
St. Jude Medical, Inc.
GE Healthcare
Cook Medical Inc.
Biosensors International Group Ltd
Nano Therapeutics Pvt. Ltd.
The detailed segments and sub-segment of the market are explained below:
By Device Type:
Closure Devices
Transcatheter Heart Valves
Atherectomy Devices
Catheters
Balloons
Stents
Others
By Procedure:
Catheter-Based Valve Implantation
Congenital Heart Defect Correction
Angioplasty
Coronary Thrombectomy
Others
By End Use:
Clinical Testing Laboratories
Hospitals
Cardiac Centers
Pediatric Clinics
Research Institutions
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
Saudi Arabia
South Africa
RoMEA
Years considered for the study are as follows:
Historical year - 2022
Base year - 2023
Forecast period - 2024 to 2032
Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.